Li, Cheryl S. W.
Sweeney, Kevin
Cronenberger, Carol
Clinical trials referenced in this document:
Documents that mention this clinical trial
Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (AvastinĀ®) in patients with advanced non-squamous non-small cell lung cancer
https://doi.org/10.1007/s00280-019-03946-8
Funding for this research was provided by:
Pfizer
Article History
Received: 13 June 2019
Accepted: 28 August 2019
First Online: 26 November 2019
Compliance with ethical standards
:
: Cheryl Li and Carol Cronenberger were employees of Pfizer at the time of study conduct. Kevin Sweeney is an employee of Pfizer. All authors hold stock in Pfizer.
: The final protocol for Study B7391003, its amendments, and informed consent documentation were reviewed and approved by the Institutional Review Boards or independent Ethics Committees at each of the participating investigational centers. The study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Council for Harmonisation Good Clinical Practice Guidelines. In addition, all local regulatory requirements were followed.
: Informed consent was obtained from all individuals who participated in the study.